Monetary Management Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-1,500
Closed -$135K – 331
2024
Q4
$135K Hold
1,500
– – 0.04% 220
2024
Q3
$148K Hold
1,500
– – 0.04% 217
2024
Q2
$139K Hold
1,500
– – 0.04% 213
2024
Q1
$142K Buy
+1,500
New +$139K 0.04% 209

Other funds holding XBI

Monetary Management Group's XBI Position: Q1 2025 in Review

Monetary Management Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 1,500 shares — an estimated $135K sold.

Monetary Management Group first reported a position in XBI in Q1 2024 and held it in 4 quarters. The position peaked at $148K in Q3 2024. 685 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

  • Monetary Management Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
  • Monetary Management Group sold 1,500 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $135K.
  • Monetary Management Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 4 quarters.
  • Monetary Management Group's State Street SPDR S&P Biotech ETF position peaked at $148K in Q3 2024.
  • 685 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Monetary Management Group's 13F filing for Q1 2025, filed 14 May 2025.